Strongbridge Bio Ord (SBBP) Stock Price, Forecast & Analysis
NASDAQ:SBBP
SBBP Key Statistics, Chart & Performance
The current stock price of SBBP is 2 null. In the past month the price decreased by -8.68%. In the past year, price decreased by -11.5%.
SBBP Technical Analysis
SBBP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SBBP. SBBP may be in some trouble as it scores bad on both profitability and health.
SBBP Financial Highlights
Over the last trailing twelve months SBBP reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 49.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -115.66% | ||
| ROA | -41.48% | ||
| ROE | N/A | ||
| Debt/Equity | 0.38 |
SBBP Forecast & Estimates
4 analysts have analysed SBBP and the average price target is 5.1 null. This implies a price increase of 155% is expected in the next year compared to the current price of 2.
For the next year, analysts expect an EPS growth of 35.78% and a revenue growth 25.01% for SBBP
SBBP Ownership
SBBP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.07 | 972.635B | ||
| JNJ | JOHNSON & JOHNSON | 20.79 | 590.688B | ||
| MRK | MERCK & CO. INC. | 22.05 | 303.948B | ||
| PFE | PFIZER INC | 9.01 | 154.026B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.99 | 124.791B | ||
| ZTS | ZOETIS INC | 18.96 | 56.827B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.68 | 26.062B | ||
| VTRS | VIATRIS INC | 6.26 | 18.521B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.57 | 13.336B | ||
| AXSM | AXSOME THERAPEUTICS INC | 195.74 | 8.278B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SBBP
Company Profile
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. The company is headquartered in Trevose, Pennsylvania and currently employs 72 full-time employees. The company went IPO on 2015-09-10. The firm is focused on the development and commercialization of therapies for a range of diseases. The firm's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The firm has a clinical-stage pipeline of therapies for endocrine diseases. The firm's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The firm is studying COR-003 for the treatment of endogenous Cushing's syndrome. The company is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Company Info
Strongbridge Bio Ord
900 Northbrook Dr Ste 200
Trevose PENNSYLVANIA 19053 US
CEO: John H. Johnson
Employees: 72
Phone: 16102549200.0
Strongbridge Bio Ord / SBBP FAQ
What does SBBP do?
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. The company is headquartered in Trevose, Pennsylvania and currently employs 72 full-time employees. The company went IPO on 2015-09-10. The firm is focused on the development and commercialization of therapies for a range of diseases. The firm's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The firm has a clinical-stage pipeline of therapies for endocrine diseases. The firm's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The firm is studying COR-003 for the treatment of endogenous Cushing's syndrome. The company is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Can you provide the latest stock price for Strongbridge Bio Ord?
The current stock price of SBBP is 2 null. The price increased by 1.52% in the last trading session.
Does Strongbridge Bio Ord pay dividends?
SBBP does not pay a dividend.
What is the ChartMill technical and fundamental rating of SBBP stock?
SBBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the number of employees for Strongbridge Bio Ord?
Strongbridge Bio Ord (SBBP) currently has 72 employees.
What is Strongbridge Bio Ord worth?
Strongbridge Bio Ord (SBBP) has a market capitalization of 135.66M null. This makes SBBP a Micro Cap stock.